Mlp Saglik Hizmetleri As Class B · BIST:MPARK
Mlp Saglik Hizmetleri As Class B — MLP Care — H1 2024 Earnings Presentation
21 slides from Mlp Saglik Hizmetleri As Class B's earnings presentation, Aug 22, 2024
Slide 1: MLP Care H1 2024 Presentation
MLPCARE H1 2024 PRESENTATION A u g u s t 2 2 th, 2 0 2 4
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently ava
Slide 3: Muharrem Usta, Chairman & CEO
MUHARREM USTA CHAIRMAN & CEO
Slide 4: Q2 2024 Financials at a Glance
Q2 2024 Financials at a Glance Revenue EBITDA • Strong growth in both top and bottom line TL 7,701 m TL 1,897 m 19% Growth 22% Growth H1 2024: H1 2024: • Revenues supported by the private 26% Growth 37% Growth medical insurance • EBITDA growth on the back of disciplined Net Debt / cost management Ne
Slide 5: MLP Care Continues to Grow
MLP Care Continues to Grow 2024 New Hospitals Bed Capacity Square Meters Opening Date Consolidated Capacity MP İncek - Ankara 182 8.225 April 16, 2024 +6.300 Bed MP Gebze - Kocaeli 100 18.000 June 24, 2024 10% MP Ataşehir – İstanbul 80 8.000 June 24, 2024 MP İzmir 143 12.500 June 28, 2024 MP
Slide 6: Hospital Management with AI
Hospital Management with AI We are developing a HMS with AI Cost Cost Efficiency Revenue Efficiency Maximization Management with AI Forecast & Variance Performance Analysis Evaluation Capacity Analysis & Optimization 6
Slide 7: Burcu Öztürk, CFO
Slide 8: Revenue Is up by 26%
Revenue Is up by 26% Revenue (TLm) 25.5% 16.331 13.011 18.6% 7.701 6.496 Q2 2023 Q2 2024 H1 2023 H1 2024 Denotes growth of Revenue vs. the same period of the last year 8
Slide 9: PMI & Top-up Insurance Lead Growth
PMI & Top-up Insurance Lead Growth H1 2024 42% 22% SSI coverage allows us to reach the 3% 3% majority of Turkish population 14% 11% Self pay increases via premium service offering and elective procedures PMI, Top-up & Contracted Institutions market share grows rapidly on the back of strong gro
Slide 10: Continued Improvement in Average Prices
Continued Improvement in Average Prices Outpatient Revenues (TLm) Inpatient Revenues (TLm) 34.1% 26.6% 20.8% 12.8% 13.3% 13.8% 1.011 762 649 817 6.522 7.512 4.862 5.932 H1 2023 Volume & Mix Price H1 2024 H1 2023 Volume & Mix Price H1 2024 Average Revenue Per Visit (ARPV) Average Revenue Per Protocol
Slide 11: EBITDA Is Up By 37%
EBITDA Is Up By 37% EBITDA (TLm)1 36.7% 25.1% 4.102 23.1% 21.6% 3.001 24.6% 24.0% 1.897 1.560 Q2 2023 Q2 2024 H1 2023 H1 2024 1 EBITDA and EBITDA margin calculated by deducting general administrative expenses from gross profit and adding depreciation and amortization expenses Denotes growth of EBITD
Slide 12: Prudent Cost Management
Prudent Cost Management Cost of Service and G&A Expenses as a % of Revenues Cost Saving Measures enables us to reach the favourable EBITDA Margin EBITDA Margin 23.1% 25.1% Material costs as a % of revenue decreased by 12,0% 9,3% 48bps due to effective inventory management 6,4% 6,1% Doctor costs
Slide 13: Bottom Line Improves on The Back of Strong Operations
Bottom Line Improves on The Back of Strong Operations Net Profit (TLm) Net Profit (TLm) Allocated to Equity Holders of the Parent 20.3% 2.055 10.6% 1.791 1.708 1.620 7.9% (3.2%) 1.240 1.149 1.085 1.051 Q2 2023 Q2 2023 H1 2023 H2 2024 Q2 2023 Q2 2024 H1 2023 H2 2024 Denotes growth/decrease of Net Pro
Slide 14: Leverage Ratio Improves
Leverage Leverage Ratio Ratio Improves Improves Total Debt Total Debt Breakdown H1 2024 7.554 Other; 309 Bank Loans; 1.064 6.368 Lease Liabilities ; 2.994 Bonds; 2.000 2023 H1 2024 Net Debt Net Debt excl. IFRS 16 4.046 1.225 3.997 1.002 0.6x 0.2x 0.5x 0.1x 2023 H1 2024 2023 H1 2024 *All figures are
Slide 15: Cash Flow
Cash Flow million TL H1 2023 H1 2024 Change WC Requirement increased due EBITDA 3.001 4.102 1.101 increase in trade receivables and Changes in working capital 672 (377) (1.049) shorter payment days. Tax paid (143) (393) (249) Taxes paid increased due to Other (194) (237) (43) increase in corpora
Slide 16: Q&A
Q&A
Slide 17: Closing Remarks
Closing Remarks MUHARREM USTA CHAIRMAN & CEO
Slide 18: Thank You!
Thank You! MLP Care Investor Relations Deniz Can Yücel +90 212 227 5555 (Ext: 1148) deniz.yucel@mlpcare.com http://investor.mlpcare.com/en/
Slide 19: Historical Balance Sheet
Historical Balance Sheet Reviewed Audited TLm June 30, 2024 December 31, 2023 Cash and cash equivalents 2,371 3,508 Trade receivables 4,932 4,562 Inventory 972 1,343 Short term other assets 991 1,139 Current assets 9,266 10,552 Tangible and intangible fixed assets 11,236 10,426 Right of use assets 9
Slide 20: Historical P&L Statements
Historical P&L Statements Reviewed Reviewed Change (%) Q2 2024 Q2 2023 Change (%) TLm H1 2024 H1 2023 Revenues 16,331 13,011 %25.5 7,701 6,496 %18.6 Cost of service (-) (12,162) (9,673) %25.7 (5,783) (4,780) %21.0 Gross profit 4,169 3,338 %24.9 1,919 1,716 %11.8 General administration expenses (-) (
Slide 21: EBITDA Reconciliation
EBITDA Reconciliation Change Change TLm H1 2024 H1 2023 (%) Q2 2024 Q2 2023 (%) Revenue 16,331 13,011 25.5% 7,701 6,496 18.6% Cost of service (12,162) (9,673) 25.7% (5,783) (4,780) 21.0% Gross profit 4,169 3,338 24.9% 1,919 1,716 11.8% General administrative expenses (-) (1,339) (1,310) 2.2% (636) (